Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 415 (final count)
- Started
- Jul 2, 2017
- Main results expected
- Apr 8, 2024
- Fully finished
- Apr 8, 2024
- Results posted
- Apr 8, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants With ≥1 Dose Limiting Toxicity (DLT)
Measured over: Up to 6 weeks
Number of Participants With ≥1 Adverse Event (AE)
Measured over: Up to approximately 77 months
Number of Participants Discontinuing Study Treatment Due to an AE
Measured over: Up to approximately 26 months
Efficacy Expansion: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Based on Adjusted Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Measured over: Up to approximately 72 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03179436 · record last updated 2025-04-08 · checked 2026-11-09 15:47 UTC